GlassScriptPhysician profile
Brian D Flanagan
NPI 1154524247
$14,100.83
in general payments reported to CMS, 2019-2025
37 companies · $6,016 in 2025
The $6,016 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,383 · 2020: $2,533 · 2021: $1,470 · 2022: $12.92 · 2023: $211 · 2024: $475 · 2025: $6,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,534 · Food and Beverage: $1,001 · Travel and Lodging: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,534.00 |
| Food and Beverage | $1,001.49 |
| Travel and Lodging | $166.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,811.54 | 2025 | |
| Glaxosmithkline, LLC. | $1,658.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,524.47 | 2019-2025 | Airsupra, Breztri |
| Csl Behring | $883.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $618.70 | 2019-2021 | |
| Insmed, INC. | $461.30 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $436.36 | 2019-2021 | |
| Electromed, INC. | $308.18 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $307.71 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $268.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $259.02 | 2019-2020 | |
| Mylan Specialty L.P. | $245.55 | 2019-2021 | |
| Pfizer INC. | $169.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $154.50 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $123.16 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $99.63 | 2019-2021 | |
| Genzyme Corporation | $95.86 | 2019-2020 | |
| Philips North America LLC | $69.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.13 | 2020-2021 | |
| Gilead Sciences, INC. | $62.93 | 2021 | |
| Shire North American Group INC | $55.08 | 2019 | |
| Amgen INC. | $53.93 | 2025 | Tezspire |
| Harmony Biosciences LLC | $49.05 | 2020 | |
| Eisai INC. | $41.81 | 2020 | |
| United Therapeutics Corporation | $38.41 | 2021 | |
| Advanced Respiratory, INC | $31.80 | 2021 | |
| Biofire Diagnostics, LLC | $26.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.02 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $20.19 | 2019 | |
| Olympus America INC. | $19.72 | 2021 | |
| Allergan, INC. | $19.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.70 | 2023 | Purified Cortrophin Gel |
| Vapotherm INC | $17.32 | 2019 | |
| Pulmonx Corporation | $16.29 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Jazz Pharmaceuticals INC. | $15.11 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.24 | 2024 | Quviviq |
| Optinose US, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.